Geron Corp. Stock Hits Day Low of $1.72 Amid Price Pressure

Geron Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline today, with its stock price dropping by 7.81% as of February 23, 2026. The stock reached an intraday low of USD 1.72, reflecting a challenging trading session. In terms of performance metrics, Geron Corp. has shown a mixed picture over various time frames. While the stock has gained 34.09% year-to-date, it has underperformed significantly over the past year, with a decline of 31.13%, contrasting sharply with the S&P 500's gain of 12.95% during the same period. Despite recent positive developments, including a 25.46% growth in operating profit and consistent positive results over the last three quarters, the company faces challenges. Its net sales for the half-year stood at USD 88.64 million, but the return on equity remains negative at -31.48%. Additionally, the stock is trading at a price-to-book ratio of 4.83, indicating a premium valuation relative to its book value. Overall, Geron Corp.'s current market position reflects a complex interplay of growth potential and ongoing performance challenges.